Company news
Imunon, Inc. (NASDAQ:IMNN) news
Imunon, Inc. news releases on 6ix. Latest, Sep 29, 2026: IMUNON Converts $1.2 Million of Debt-to-Equity
Press releases & updates
IMUNON Converts $1.2 Million of Debt-to-Equity
September 28, 2026
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
September 22, 2026
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
September 10, 2026
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
September 9, 2026
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
August 26, 2026
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
July 30, 2026
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
July 23, 2026
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
July 21, 2026
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
June 22, 2026
IMUNON to Present at the Life Sciences Investor Forum on June 25th
June 22, 2026
IMUNON Announces Up to $10 Million Cash Financing
June 3, 2026
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
May 5, 2026
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
March 30, 2026
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
March 24, 2026
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
March 23, 2026
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
February 5, 2026
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
December 30, 2025
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
December 29, 2025
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
November 10, 2025
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
November 10, 2025
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
November 7, 2025
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
November 6, 2025
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
November 4, 2025
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
October 30, 2025
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
October 23, 2025
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
October 19, 2025
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
October 17, 2025
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
October 14, 2025
IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment…
September 23, 2025
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
September 22, 2025
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
September 19, 2025
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
August 28, 2025
IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…
August 7, 2025
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
August 5, 2025
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
July 30, 2025
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
July 29, 2025
IMUNON Announces Stock Dividend Boosting Shareholder Value
July 28, 2025
IMUNON Announces Reverse Stock Split
July 23, 2025
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
July 15, 2025
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
June 30, 2025
IMNN: Translational Data from OVATION 2 Presented…
June 20, 2025
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
June 18, 2025
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
June 17, 2025
Life Sciences Investor Forum: Now Available for Online Viewing
June 13, 2025
Life Sciences Investor Forum Agenda Announced for June 11th-12th
June 10, 2025